Abstract CT052: A phase IB study of mRNA-based active cancer vaccine, BI1361849, combined with durvalumab and tremelimumab immunotherapy in patients with non-small cell lung cancer (NSCLC)Dung‐Tsa Chen, Jhanelle E. Gray, Toni Ricciardi et al.|Cancer Research|2024Cited by 6